Publikasi Scopus FKUI Tahun 2010 s/d 2020 (data Per 3 Februari 2021)

Louisa M., Takeuchi M., Takeuchi M., Nafrialdi, Setiabudy R.
41461551400;41462018200;7402804746;8521176100;6602316235;
Incretin-based therapies for type 2 diabetes mellitus in Asian patients: Analysis of clinical trials
2010
Medical Journal of Indonesia
19
3
205
212
8
Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Biostatistics and Clinical Medicine, Kitasato University, Indonesia
Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Takeuchi, M., Department of Biostatistics and Clinical Medicine, Kitasato University, Indonesia; Takeuchi, M., Department of Biostatistics and Clinical Medicine, Kitasato University, Indonesia; Nafrialdi, Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Setiabudy, R., Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
Aim To review the efficacy and safety data on incretin-based therapies currently available (exenatide, liraglutide, sitagliptin, vildagliptin) for the treatment of type 2 diabetes mellitus in Asian population. Methods We conducted Medline search of all relevant randomized clinical trials of incretin-based therapies for type 2 diabetes mellitus in Asian populations. Data pertinent to the efficacy and safety of GLP-1 mimetics and DPP-4 inhibitors were extracted and used. Results We found 14 randomized controlled trials of incretin based-therapy which included 3567 type 2 diabetes mellitus in Asian population (Japanese, Chinese, Korean, Indian). It was shown that incretin-based therapies improved HbA1c at higher extent (up to -1.42% in exenatide 10 mcg bid, -1.85% for liraglutide 0.9 mg qd, -1.4% for sitagliptin 100 mg and -1.4% for vildagliptin 50 mg bid) compared to the effects observed in studies with Caucasian population, with comparable safety profile. Conclusion The efficacy of incretin-based therapies in Asian patients improved glycemic parameters in a higher magnitude on some glycemic parameters compared with those in Caucasian population. These results indicate that incretin-based therapies may be more effective in Asian population than in Caucasian. © 2010, Faculty of Medicine, Universitas Indonesia. All rights reserved.
Exenatide; Incretin; Liraglutide; Sitagliptin; Type-2 diabetes; Vildagliptin
dipeptidyl peptidase IV inhibitor; exendin 4; glucagon like peptide 1; glucagon like peptide 1 receptor agonist; hemoglobin A1c; incretin; liraglutide; metformin; pioglitazone; sitagliptin; vildagliptin; Article; Asian; Caucasian; Chinese; drug efficacy; drug safety; glucotoxicity; glycemic control; homeostasis model assessment; human; Indian; insulin resistance; Japanese (people); Korean (people); lipotoxicity; non insulin dependent diabetes mellitus; pancreas islet beta cell; randomized controlled trial (topic)
Faculty of Medicine, Universitas Indonesia
08531773
Article
Q4